A gutless adenoviral vector expressing full-length anti-her2 antibody

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 9, 2009, Pages

  Jiang, Ming Hong ^a   Chen, Lin ^b   Li, Lin Fang ^a   Wu, Hong Ping ^a   Jiang, Li Hua ^a   Qian, Yan Zhen ^a   Fang, Guo En ^b   Xue, Xu Chao ^b  

^a Laboratory of Viral and Gene Therapy   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gene therapy; Gutless adenovirus; Monoclonal antibody

Indexed keywords

ADENOVIRUS VECTOR; HER2 ANTIBODY; MONOCLONAL ANTIBODY; RECOMBINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONSTRUCT; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HELPER VIRUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MACROMOLECULE; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADENOVIRIDAE; ANTIBODIES, MONOCLONAL, HUMANIZED; BACTERIOPHAGE LAMBDA; BINDING SITES, ANTIBODY; BLOTTING, WESTERN; CELL MEMBRANE; CLONING, MOLECULAR; DNA NUCLEOTIDYLTRANSFERASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; RECEPTOR, ERBB-2; TIME FACTORS; TRANSFECTION;

EID: 69949086738     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05175.x     Document Type: Article

References (41)

1. Haq B, Geyer CE. Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. Womens Health 2009 5 : 135 147.
2. Chia S, Norris B, Speers C et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J. Clin. Oncol. 2008 26 : 5697 5704.
3. Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F. HER2/neu role in breast cancer: From a prognostic foe to a predictive friend. Curr. Opin. Obstet. Gynecol. 2007 19 : 56 62.
4. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol. 2009 15 Jan 2009 [Epub ahead of print].
5. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin. Cancer Res. 2001 7 (Suppl. S4436 42.
6. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur. J. Nucl. Med. Mol. Imaging 2004 31 (Suppl. 1 S149 61.
7. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin. Breast Cancer 2008 8 : 324 333.
8. Valabrega G, Montemurro F, Aglietta M. Trastuzumb: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 2007 18 : 977 984.
9. Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: Trastuzumab and beyond. Expert Opin. Pharmacother. 2008 9 : 2583 2601.
10. Nahta R, Esteva FJ. Herceptin: Mechanisms of action and resistance. Cancer Lett. 2006 232 : 123 138.
11. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet 2007 369 : 29 36.
12. Moorhead JW, Clayton GH, Smith RL, Schaack J. A replication-incompetent adenovirus vetcor with the preterminal protein gene deleted efficiently transduces mouse ears. J. Virol. 1999 72 : 1046 1053.
13. Xu ZL, Mizuguchi HM, Sakurai F et al. Approaches to improving the kinetics of adenovius-delivered genes and gene products. Adv. Drug Deliv. Rev. 2005 57 : 781 802.
14. Alba R, Bosch A, Chillon M. Gutless adenovirus: Last-generation adenovirus for gene therapy. Gene Ther. 2005 12 (Suppl S18 27.
15. Wang L, Hernandez-Alcoceba R, Shankar V et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: A potential for liver cancer. Gastroenterology 2004 126 : 278 289.
16. Brunetti-Pierri N, Palmer DJ, Mane V, Finegold M, Beaudet AL, Ng P. Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors. Mol. Ther. 2005 12 : 99 106.
17. Brunetti-Pierri N, Ng T, Iannitti DA et al. Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum. Gene Ther. 2006 17 : 391 404.
18. Puntel M, Curtin JF, Zirger JM et al. Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction. Hum. Gene Ther. 2006 17 : 531 544.
19. Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res. 2006 16 : 182 188.
20. Guo MG, Jiang MH, Yang Q et al. Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene. Zhonghua Yi Xue Za Zhi 2004 84 : 1147 1151 (in Chinese).
21. Jiang M, Shi W, Zhang Q et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin. Cancer Res. 2006 12 : 6179 6185.
22. Carter PJ, Presta LG, inventors. Genentech Company, assignee. Immunoglobulin variants. US patent no. 5821337. 13 October 1998.
23. Umana P, Gerdes CA, Stone D et al. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat. Biotechnol. 2001 19 : 582 585.
24. Callahan SM, Ming X, Lu SK, Brunner LJ, Croyle MA. Considerations for use of recombinant adenoviral vectors: Dose effect on hepatic cytochromes P450. J. Pharmacol. Exp. Ther. 2005 312 : 492 501.
25. Blanche F, Cameron B, Barbot A et al. An improved anion-exchange HPLC method for the detection and purification of adenoviral particles. Gene Ther. 2000 7 : 1055 1062.
26. Binyamin L, Borghaei H, Weiner LM. Cancer therapy with engineered monoclonal antibodies. Update Cancer Ther. 2006 1 : 147 157.
27. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: New prospects for antibodies and immunoconjugates. CA Cancer J. Clin. 2006 56 : 226 243.
28. Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim. Biophys. Acta 2007 1776 : 108 123. (Pubitemid 47332077)
29. Sanz L, Blanco B, Alvarez-Vallina L. Antibodies and gene therapy: Teaching old magic bullets new tricks. Trends Immunol. 2004 25 : 85 91.
30. Zhang Q, Chen G, Liu X, Qian Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res. 2007 17 : 89 99.
31. Fang J, Qian JJ, Yi S et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 2005 23 : 584 590.
32. Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur. J. Cancer 2007 43 : 497 509.
33. Tokunaga E, Oki E, Nishida K et al. Trastuzumab and breast cancer: Developments and current status. Int. J. Clin. Oncol. 2006 11 : 199 208.
34. Castro M, Goverdhana S, Hu J, Jovel N, Yuan X, Lowenstein P. Gene therapy for pituitary tumors: From preclinical models to clinical implementation. Front. Neuroendocrinol. 2003 24 : 62 77.
35. Martina Y, Avitablie D, Piersanti S, Cherubini G, Saggio I. Different modulation of cellular transcription by adenovirus 5, DeltaE1/E3 adenovirus and helper-dependent vectors. Virus Res. 2007 130 : 71 84.
36. Wang L, Hernandez-Alcoceba R, Shankar V et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: A potential therapy for liver cancer. Gastroenterology 2004 126 : 278 289.
37. O'Neal WK, Zhou H, Morral N et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol. Med. 2000 6 : 179 195.
38. Curtis MD, Grossniklaus U. A gateway cloning vector set for high-throughput functional analysis of genes in planta. Plant Physiol. 2003 133 : 462 469.
39. Zhao YP, Bai WJ, Yan Z et al. Construction of an antisense RNA recombinant adenovirus vector of the human PDE5A1 gene promoter. Zhonghua Nan Ke Xue 2005 11 : 331 334 (in Chinese).
40. Ng P, Beauchamp C, Evelegh C, Parks R, Graham FL. Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol. Ther. 2001 3 : 809 815.
41. Kreppel F, Kochanek S. Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J. Virol. 2004 78 : 9 22.